AGP Picks
View all

Lunsumio market seen growing on rising blood cancer cases

Nov. 4, 2026
Lunsumio market seen growing on rising blood cancer cases
By AI, Created 18:45 UTC, Nov 04, 2026, AGP -

The Business Research Company says the global market for Lunsumio, a bispecific antibody therapy for relapsed or refractory follicular lymphoma, is set to expand through 2035 as cancer treatment shifts toward personalized immuno-oncology. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - The Lunsumio market is tied to rising demand for new blood cancer treatments, especially for patients with relapsed or refractory follicular lymphoma. - The drug sits in a fast-growing segment of oncology that includes bispecific antibodies, T-cell engaging immunotherapies and precision oncology. - The market outlook matters because the report points to sustained growth through 2035, driven by cancer incidence and treatment innovation.

What happened: - The Business Research Company published its Lunsumio Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The report says Lunsumio, also known as mosunetuzumab, is a bispecific antibody for patients with relapsed or refractory follicular lymphoma. - The therapy targets CD20 on B-cells and CD3 on T-cells to help the immune system attack cancer cells. - The report says the market gained traction in the historical period because of rising non-Hodgkin lymphoma cases, limited options for relapsed follicular lymphoma, more oncology clinical trials, progress in antibody engineering and new immunotherapy approvals.

The details: - The report expects growth to accelerate as personalized cancer treatment and immuno-oncology combinations become more widely used. - The report also points to rising investment in oncology biologics, stronger demand for outpatient cancer therapies and ongoing bispecific antibody innovation. - Key forecast-period trends include broader use of bispecific antibody therapies, more emphasis on T-cell engaging immunotherapies and growth in precision oncology. - Targeted therapies for relapsed lymphomas and biomarker-based patient selection are identified as important development areas. - Blood cancers remain a major market driver because they affect blood cell production and function and often begin in bone marrow or lymphatic tissue. - Common blood cancers include leukemia, lymphoma and myeloma. - The report links rising blood cancer cases to aging populations, genetic susceptibility, environmental exposure, weakened immune systems, lifestyle habits and improved diagnosis. - The American Cancer Society reported 62,770 leukemia cases in the US for 2024, up from 59,610 in 2023. - The report says Lunsumio is used for patients who have exhausted other treatment options. - North America held the largest share of the Lunsumio market in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report also covers Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The report’s emphasis on biomarker selection and precision oncology suggests the market is moving toward more targeted use, not broader mass adoption. - The regional outlook implies established treatment access in North America and faster expansion opportunities in Asia-Pacific. - The inclusion of TAM analysis, company scoring matrices, dashboards and market hotspots suggests the report is aimed at investors and strategy teams, not just clinical readers.

What's next: - The report expects continued market expansion through 2035 as immuno-oncology combinations and bispecific antibodies gain ground. - Further growth will likely depend on new oncology biologics, better patient selection and continued adoption of outpatient cancer care. - The company also says its 2026 reports now include expanded strategic intelligence, updated graphics and tables, and new analysis tools such as market attractiveness scoring and Excel-based dashboards.

The bottom line: - Lunsumio is positioned as part of a broader shift in blood cancer treatment toward targeted immune-based therapies, and the market data points to long-term growth rather than a short-term spike.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Africa News Guide

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Africa News Guide

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.